CareDx Showcases Latest Innovation in Transplantation at European EFI 2022 Conference

Posters and Symposium Feature Latest Advances in AlloSeq Portfolio Including HLA Typing and Hematopoietic Stem Cell and Organ Transplant Monitoring

SOUTH SAN FRANCISCO, Calif., May 11, 2022 (GLOBE NEWSWIRE) — CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will be presenting the latest information on its AlloSeq® portfolio of pre- and post-transplant solutions for human leukocyte antigen (HLA) typing, including QTYPE®, and post-transplant hematopoietic stem cell and organ transplant surveillance during poster presentations and the symposium taking place at this year’s EFI 2022 Conference. Read the complete press release on CareDx.com.